CMPR Director Li Zili Pledges to Build a Globally Trusted Regulator
Start here
On 26 October 2026, the South China Morning Post reported that Li Zili, director of the Hong Kong medical device and drug regulator CMPR, pledged to build a fully capable and globally trusted regulator that acts as a catalyst for medical innovation rather than merely a "scaled-down version" of existing overseas models. He noted that many places in Asia, such as the mainland, Singapore and Japan, established regulators long ago, while Hong Kong has its own distinctive features. The report did not mention a specific timetable or details of measures.
Generated by AI from reporting · updated 1 hour ago
Reporting timeline
Follow the reports to explore different aspects of the story.
- 南華早報·香港Hong Kong New Drug and Device Regulator CMPR Director Li Zili Pledges to Build Global Trust and Drive Innovation
Li Zili, Director of Hong Kong's Centre for Medical Products Regulation (CMPR), pledged to build a fully capable and globally trusted regulator that acts as a catalyst for medical innovation rather than merely a "scaled-down version" of existing overseas models. He noted that many places in Asia, such as the mainland, Singapore and Japan, established regulators long ago, while Hong Kong has its own unique characteristics.
Activity over time for this story
There are not enough continuous observations to draw a trend yet.